{"id": "article-159936_0", "title": "Eletriptan -- Indications", "content": "Eletriptan is a medication approved by the U.S. Food and Drug Administration (FDA) to treat acute migraine headaches in adults, with or without aura.\u00a0Eletriptan was discovered\u00a0during research on serotonin receptors\u2014the neurotransmitter associated with migraine pathophysiology. [1] Serotonin can induce vasoconstriction of cranial blood vessels, thereby alleviating migraine pain. [1] However, serotonin can also cause adverse effects by affecting different receptors. Eletriptan demonstrated notable affinity and selectivity for the 5-HT(1B/1D/1F) receptors involved in migraines. [2] This drug belongs to a class of medications commonly known as 'triptans,' which are serotonin receptor agonists. [3]", "contents": "Eletriptan -- Indications. Eletriptan is a medication approved by the U.S. Food and Drug Administration (FDA) to treat acute migraine headaches in adults, with or without aura.\u00a0Eletriptan was discovered\u00a0during research on serotonin receptors\u2014the neurotransmitter associated with migraine pathophysiology. [1] Serotonin can induce vasoconstriction of cranial blood vessels, thereby alleviating migraine pain. [1] However, serotonin can also cause adverse effects by affecting different receptors. Eletriptan demonstrated notable affinity and selectivity for the 5-HT(1B/1D/1F) receptors involved in migraines. [2] This drug belongs to a class of medications commonly known as 'triptans,' which are serotonin receptor agonists. [3]"}
{"id": "article-159936_1", "title": "Eletriptan -- Indications", "content": "Currently, there is insufficient significant data advocating for the use of eletriptan in the treatment of pediatric migraine headaches despite the utilization of other triptans for this purpose. [4] Eletriptan was evaluated in several randomized controlled trials involving patients with moderate-to-severe migraines, with or without aura. The primary endpoint measured was the pain-free response 2 hours after taking the medication. The secondary endpoints included pain relief, sustained pain-free response, recurrence rate, use of rescue medication, and adverse events. The results revealed that eletriptan exhibited superiority over placebo and demonstrated comparable or superior efficacy and tolerability to other triptans. [5]", "contents": "Eletriptan -- Indications. Currently, there is insufficient significant data advocating for the use of eletriptan in the treatment of pediatric migraine headaches despite the utilization of other triptans for this purpose. [4] Eletriptan was evaluated in several randomized controlled trials involving patients with moderate-to-severe migraines, with or without aura. The primary endpoint measured was the pain-free response 2 hours after taking the medication. The secondary endpoints included pain relief, sustained pain-free response, recurrence rate, use of rescue medication, and adverse events. The results revealed that eletriptan exhibited superiority over placebo and demonstrated comparable or superior efficacy and tolerability to other triptans. [5]"}
{"id": "article-159936_2", "title": "Eletriptan -- Indications", "content": "Several trials also explored the effects of eletriptan on migraine pain of varying intensities, comparing mild versus moderate-to-severe pain. The findings indicated that early intervention with eletriptan during mild pain yielded better outcomes than delaying treatment until the pain escalated to moderate-to-severe levels. [6]", "contents": "Eletriptan -- Indications. Several trials also explored the effects of eletriptan on migraine pain of varying intensities, comparing mild versus moderate-to-severe pain. The findings indicated that early intervention with eletriptan during mild pain yielded better outcomes than delaying treatment until the pain escalated to moderate-to-severe levels. [6]"}
{"id": "article-159936_3", "title": "Eletriptan -- Indications -- FDA-Approved Indications", "content": "Eletriptan received approval from the FDA in December 2002 for treating acute migraines in adults, both with and without aura. [7] The approval was based on the data from the clinical trials that indicated the safety and efficacy of eletriptan in various doses and conditions. [8] The American Headache Society (AHS) advocates for the use of triptans, including eletriptan, as an A-level recommendation for the acute treatment of migraines in adults. [9]", "contents": "Eletriptan -- Indications -- FDA-Approved Indications. Eletriptan received approval from the FDA in December 2002 for treating acute migraines in adults, both with and without aura. [7] The approval was based on the data from the clinical trials that indicated the safety and efficacy of eletriptan in various doses and conditions. [8] The American Headache Society (AHS) advocates for the use of triptans, including eletriptan, as an A-level recommendation for the acute treatment of migraines in adults. [9]"}
{"id": "article-159936_4", "title": "Eletriptan -- Indications -- Off-Label Uses", "content": "Research has indicated a potential off-label application of eletriptan in the short-term prophylaxis of cluster headaches in adults. However, additional studies are required to validate these findings. [10] Currently, other triptans, such as sumatriptan, have FDA approval for the acute treatment of cluster headaches. [11]", "contents": "Eletriptan -- Indications -- Off-Label Uses. Research has indicated a potential off-label application of eletriptan in the short-term prophylaxis of cluster headaches in adults. However, additional studies are required to validate these findings. [10] Currently, other triptans, such as sumatriptan, have FDA approval for the acute treatment of cluster headaches. [11]"}
{"id": "article-159936_5", "title": "Eletriptan -- Mechanism of Action", "content": "Eletriptan belongs to the class of organic compounds known as indoles, specifically a methylpyrrolidinyltryptamine substituted with a benzene sulfonyl derivative. In understanding the pathophysiology of migraines, various neurotransmitters, neuropeptides, and neurochemical systems contribute to the pain associated with this condition. The 3 primary components of migraine pathophysiology include vasodilation, particularly of the cerebral and meningeal arteries, neurogenic inflammation, and activation of the trigeminovascular system. [12] [13] [14]", "contents": "Eletriptan -- Mechanism of Action. Eletriptan belongs to the class of organic compounds known as indoles, specifically a methylpyrrolidinyltryptamine substituted with a benzene sulfonyl derivative. In understanding the pathophysiology of migraines, various neurotransmitters, neuropeptides, and neurochemical systems contribute to the pain associated with this condition. The 3 primary components of migraine pathophysiology include vasodilation, particularly of the cerebral and meningeal arteries, neurogenic inflammation, and activation of the trigeminovascular system. [12] [13] [14]"}
{"id": "article-159936_6", "title": "Eletriptan -- Mechanism of Action", "content": "Eletriptan exerts its potency as a serotonin receptor agonist, specifically targeting the 5-HT(1B/1D) receptor. [15] The distribution of 5-HT(1B) receptors encompasses the meningeal and coronary arteries, whereas 5-HT(1D) receptors are predominantly located on the presynaptic endings of the trigeminal nerve. Consequently, 5-HT(1B) receptor agonism leads to vasoconstriction in the coronary, cerebral, and peripheral arteries. On the other hand, 5-HT(1D) receptor agonism inhibits vascular inflammation in the dura mater and neuropeptide release from trigeminal nerve terminals. [16] [13] The dual effect of 5-HT(1B/1D) receptor agonism results in a decrease in perceived pain during an acute migraine attack.", "contents": "Eletriptan -- Mechanism of Action. Eletriptan exerts its potency as a serotonin receptor agonist, specifically targeting the 5-HT(1B/1D) receptor. [15] The distribution of 5-HT(1B) receptors encompasses the meningeal and coronary arteries, whereas 5-HT(1D) receptors are predominantly located on the presynaptic endings of the trigeminal nerve. Consequently, 5-HT(1B) receptor agonism leads to vasoconstriction in the coronary, cerebral, and peripheral arteries. On the other hand, 5-HT(1D) receptor agonism inhibits vascular inflammation in the dura mater and neuropeptide release from trigeminal nerve terminals. [16] [13] The dual effect of 5-HT(1B/1D) receptor agonism results in a decrease in perceived pain during an acute migraine attack."}
{"id": "article-159936_7", "title": "Eletriptan -- Mechanism of Action", "content": "The activation of the trigeminovascular system is believed to underlie the majority of the pathophysiology of migraine pain. This includes processes such as plasma extravasation, vasodilation, heightened nociceptive transmission (via the release of neuropeptides like calcitonin gene-related peptide and adenylate cyclase-activating protein), and activation of mast cells. Activation of the trigeminovascular system is also responsible for the classic migraine characteristics, manifesting as the pulsating nature of pain and the unilateral, anterior, and periorbital distribution. [13]", "contents": "Eletriptan -- Mechanism of Action. The activation of the trigeminovascular system is believed to underlie the majority of the pathophysiology of migraine pain. This includes processes such as plasma extravasation, vasodilation, heightened nociceptive transmission (via the release of neuropeptides like calcitonin gene-related peptide and adenylate cyclase-activating protein), and activation of mast cells. Activation of the trigeminovascular system is also responsible for the classic migraine characteristics, manifesting as the pulsating nature of pain and the unilateral, anterior, and periorbital distribution. [13]"}
{"id": "article-159936_8", "title": "Eletriptan -- Mechanism of Action", "content": "The interaction of eletriptan with 5-HT1B and 5-HT1D receptors by eletriptan initiates a cascade of intracellular events. Activation of 5-HT(1B/1D) receptors leads to the inhibition of adenylate cyclase activity through the G\u03b1i protein subunit, resulting in diminished cAMP levels. [17] This reduction in cAMP levels subsequently mitigates the activation of protein kinase A, which reduces the phosphorylation of essential proteins involved in neuronal excitation and sensitization. Furthermore, the activation of G-protein\u2013coupled inwardly rectifying potassium (GIRK) channels by G\u03b2\u03b3 subunits, liberated upon G-protein\u2013coupled receptor (GPCR) activation, induces neuronal hyperpolarization. This hyperpolarization actively suppresses neuronal firing and curtails neurotransmitter release, thereby contributing to an overall reduction in neurogenic inflammation. Although there is evidence suggesting eletriptan's affinity for 5-HT(1A), 5-HT(1F), 5-HT(2E), and 5-HT(7) receptors, no identified clinical effects are linked to the involvement of these receptors. [1]", "contents": "Eletriptan -- Mechanism of Action. The interaction of eletriptan with 5-HT1B and 5-HT1D receptors by eletriptan initiates a cascade of intracellular events. Activation of 5-HT(1B/1D) receptors leads to the inhibition of adenylate cyclase activity through the G\u03b1i protein subunit, resulting in diminished cAMP levels. [17] This reduction in cAMP levels subsequently mitigates the activation of protein kinase A, which reduces the phosphorylation of essential proteins involved in neuronal excitation and sensitization. Furthermore, the activation of G-protein\u2013coupled inwardly rectifying potassium (GIRK) channels by G\u03b2\u03b3 subunits, liberated upon G-protein\u2013coupled receptor (GPCR) activation, induces neuronal hyperpolarization. This hyperpolarization actively suppresses neuronal firing and curtails neurotransmitter release, thereby contributing to an overall reduction in neurogenic inflammation. Although there is evidence suggesting eletriptan's affinity for 5-HT(1A), 5-HT(1F), 5-HT(2E), and 5-HT(7) receptors, no identified clinical effects are linked to the involvement of these receptors. [1]"}
{"id": "article-159936_9", "title": "Eletriptan -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: Following\u00a0oral administration, eletriptan undergoes rapid absorption from the gastrointestinal tract, with peak plasma concentration (Tmax) typically occurring around 1.5 and 2 hours. The median time to reach peak plasma levels is 2 to 4 hours. Eletriptan exhibits an absolute bioavailability of approximately 50%. Administration with a high-fat meal increases the peak concentration (Cmax) and area under the curve (AUC) of eletriptan by about 20% to 30%. Distribution: Eletriptan has a volume of distribution of 138 L, and its plasma protein binding is moderate, accounting for approximately 85%. [7]", "contents": "Eletriptan -- Mechanism of Action -- Pharmacokinetics. Absorption: Following\u00a0oral administration, eletriptan undergoes rapid absorption from the gastrointestinal tract, with peak plasma concentration (Tmax) typically occurring around 1.5 and 2 hours. The median time to reach peak plasma levels is 2 to 4 hours. Eletriptan exhibits an absolute bioavailability of approximately 50%. Administration with a high-fat meal increases the peak concentration (Cmax) and area under the curve (AUC) of eletriptan by about 20% to 30%. Distribution: Eletriptan has a volume of distribution of 138 L, and its plasma protein binding is moderate, accounting for approximately 85%. [7]"}
{"id": "article-159936_10", "title": "Eletriptan -- Mechanism of Action -- Pharmacokinetics", "content": "Metabolism: Eletriptan undergoes extensive metabolism primarily in the liver, predominantly by the cytochrome P450 3A4 (CYP3A4) enzyme. [18] The sole active metabolite is the N -demethylated form of eletriptan, exhibiting approximately 10% of the potency of the parent compound. Other minor metabolites include the N -oxide, the indole acetic acid derivative, and their glucuronides.", "contents": "Eletriptan -- Mechanism of Action -- Pharmacokinetics. Metabolism: Eletriptan undergoes extensive metabolism primarily in the liver, predominantly by the cytochrome P450 3A4 (CYP3A4) enzyme. [18] The sole active metabolite is the N -demethylated form of eletriptan, exhibiting approximately 10% of the potency of the parent compound. Other minor metabolites include the N -oxide, the indole acetic acid derivative, and their glucuronides."}
{"id": "article-159936_11", "title": "Eletriptan -- Mechanism of Action -- Pharmacokinetics", "content": "Elimination: Eletriptan and its metabolites undergo elimination primarily through urine and feces. In the general population, eletriptan has a mean terminal elimination half-life of approximately 4 hours, whereas in the geriatric population, the half-life ranges between 4.4 and 5.7 hours. [19] The non-renal pathway contributes 90% of the overall clearance, with renal clearance contributing only 10%. [20]", "contents": "Eletriptan -- Mechanism of Action -- Pharmacokinetics. Elimination: Eletriptan and its metabolites undergo elimination primarily through urine and feces. In the general population, eletriptan has a mean terminal elimination half-life of approximately 4 hours, whereas in the geriatric population, the half-life ranges between 4.4 and 5.7 hours. [19] The non-renal pathway contributes 90% of the overall clearance, with renal clearance contributing only 10%. [20]"}
{"id": "article-159936_12", "title": "Eletriptan -- Administration -- Available Dosage Forms and Strengths", "content": "Currently, eletriptan is exclusively available in oral tablet form, distinguishing it from other drugs in the triptan class, which come in various formulations such as nasal sprays, oral tablets, oral disintegrating tablets, and subcutaneous injections. [21] [22] [23] Ongoing exploration is underway to develop alternative formulations of eletriptan. [24] [25] Eletriptan was formulated as an oral tablet and is offered in 2 strengths\u201420 mg and 40 mg.", "contents": "Eletriptan -- Administration -- Available Dosage Forms and Strengths. Currently, eletriptan is exclusively available in oral tablet form, distinguishing it from other drugs in the triptan class, which come in various formulations such as nasal sprays, oral tablets, oral disintegrating tablets, and subcutaneous injections. [21] [22] [23] Ongoing exploration is underway to develop alternative formulations of eletriptan. [24] [25] Eletriptan was formulated as an oral tablet and is offered in 2 strengths\u201420 mg and 40 mg."}
{"id": "article-159936_13", "title": "Eletriptan -- Administration -- Adult Dosage", "content": "Eletriptan is administered orally and is characterized by high lipophilicity. [26] The recommended doses are 20 mg or 40 mg, with a preference for a single dose of 40 mg due to enhanced efficacy. [27] If the initial dose of eletriptan proves ineffective, a second dose can be taken within 12 to 24 hours of the first dose, with a maximum recommended dose of 80 mg within a 24-hour period. [28] Similar to all other triptans, eletriptan should not be used more than twice weekly. [29]", "contents": "Eletriptan -- Administration -- Adult Dosage. Eletriptan is administered orally and is characterized by high lipophilicity. [26] The recommended doses are 20 mg or 40 mg, with a preference for a single dose of 40 mg due to enhanced efficacy. [27] If the initial dose of eletriptan proves ineffective, a second dose can be taken within 12 to 24 hours of the first dose, with a maximum recommended dose of 80 mg within a 24-hour period. [28] Similar to all other triptans, eletriptan should not be used more than twice weekly. [29]"}
{"id": "article-159936_14", "title": "Eletriptan -- Administration -- Adult Dosage", "content": "The development of central sensitization, involving the sensitization of neurons in the brain's ascending trigeminal pathways, can notably influence the efficacy of triptan therapy. [14] [30] Therefore, patients\u00a0are instructed to take eletriptan at the onset of the migraine attack, especially during the headache phase in individuals with aura, as eletriptan proves ineffective if taken during the aura phase and before the onset of the headache. [31] Efficacy data show eletriptan's superiority over other triptans at both 2 and 24 hours after administration. [19]", "contents": "Eletriptan -- Administration -- Adult Dosage. The development of central sensitization, involving the sensitization of neurons in the brain's ascending trigeminal pathways, can notably influence the efficacy of triptan therapy. [14] [30] Therefore, patients\u00a0are instructed to take eletriptan at the onset of the migraine attack, especially during the headache phase in individuals with aura, as eletriptan proves ineffective if taken during the aura phase and before the onset of the headache. [31] Efficacy data show eletriptan's superiority over other triptans at both 2 and 24 hours after administration. [19]"}
{"id": "article-159936_15", "title": "Eletriptan -- Administration -- Specific Patient Populations", "content": "Hepatic impairment: No dosage adjustment of eletriptan is necessary for mild-to-moderate hepatic impairment. However, the use of eletriptan is not recommended for individuals with severe hepatic impairment. Eletriptan undergoes extensive metabolism mediated by the liver enzyme CYP3A4, and its clearance may be diminished in individuals with hepatic impairment. Some experts recommend considering a lower dose of 20 mg for patients with moderate hepatic impairment. [32]", "contents": "Eletriptan -- Administration -- Specific Patient Populations. Hepatic impairment: No dosage adjustment of eletriptan is necessary for mild-to-moderate hepatic impairment. However, the use of eletriptan is not recommended for individuals with severe hepatic impairment. Eletriptan undergoes extensive metabolism mediated by the liver enzyme CYP3A4, and its clearance may be diminished in individuals with hepatic impairment. Some experts recommend considering a lower dose of 20 mg for patients with moderate hepatic impairment. [32]"}
{"id": "article-159936_16", "title": "Eletriptan -- Administration -- Specific Patient Populations", "content": "Renal impairment: Eletriptan does not appear to be significantly affected by renal function, and no dosage adjustment of eletriptan is recommended for patients with mild, moderate, or severe renal impairment. However, as patients with renal impairment may have an increased risk of hypertension, it is advisable to monitor their blood pressure levels after the administration of eletriptan.", "contents": "Eletriptan -- Administration -- Specific Patient Populations. Renal impairment: Eletriptan does not appear to be significantly affected by renal function, and no dosage adjustment of eletriptan is recommended for patients with mild, moderate, or severe renal impairment. However, as patients with renal impairment may have an increased risk of hypertension, it is advisable to monitor their blood pressure levels after the administration of eletriptan."}
{"id": "article-159936_17", "title": "Eletriptan -- Administration -- Specific Patient Populations", "content": "Pregnancy considerations: Triptans are not the preferred first-line treatment for pregnant patients with migraines. [33] Limited data exist on the safety and efficacy of eletriptan in pregnant women. Animal studies have shown some evidence of developmental toxicity at high doses. Eletriptan is categorized as an FDA pregnancy category C and category B1 drug by the Australian Therapeutic Goods Administration (TGA), indicating that there might be situations where the potential benefits outweigh the potential risks. However, most guidelines recommend avoiding the use of eletriptan during pregnancy unless deemed necessary.", "contents": "Eletriptan -- Administration -- Specific Patient Populations. Pregnancy considerations: Triptans are not the preferred first-line treatment for pregnant patients with migraines. [33] Limited data exist on the safety and efficacy of eletriptan in pregnant women. Animal studies have shown some evidence of developmental toxicity at high doses. Eletriptan is categorized as an FDA pregnancy category C and category B1 drug by the Australian Therapeutic Goods Administration (TGA), indicating that there might be situations where the potential benefits outweigh the potential risks. However, most guidelines recommend avoiding the use of eletriptan during pregnancy unless deemed necessary."}
{"id": "article-159936_18", "title": "Eletriptan -- Administration -- Specific Patient Populations", "content": "Breastfeeding considerations: Eletriptan is excreted into human milk in small amounts, and the concentration of its active metabolite is unknown. The relative infant dose of eletriptan is significantly lower than the maternal dose, estimated to be less than 1%, making it unlikely to cause adverse effects in breastfed infants. [34] To minimize infant exposure, it is advisable to avoid breastfeeding for 24 hours after taking eletriptan.", "contents": "Eletriptan -- Administration -- Specific Patient Populations. Breastfeeding considerations: Eletriptan is excreted into human milk in small amounts, and the concentration of its active metabolite is unknown. The relative infant dose of eletriptan is significantly lower than the maternal dose, estimated to be less than 1%, making it unlikely to cause adverse effects in breastfed infants. [34] To minimize infant exposure, it is advisable to avoid breastfeeding for 24 hours after taking eletriptan."}
{"id": "article-159936_19", "title": "Eletriptan -- Administration -- Specific Patient Populations", "content": "Pediatric patients: Eletriptan has not been studied in children younger than 18, and thus, it is\u00a0not approved for use in pediatric patients due to a lack of safety and efficacy studies in this population. [4] According to AHS guidelines, no evidence suggests that administering eletriptan OT 40 mg to adolescents increases the likelihood of experiencing headache pain response after 2 hours compared to those who receive a placebo. Notably, the FDA has approved almotriptan, rizatriptan, and zolmitriptan for treating migraines in individuals aged 12 to 17. [35]", "contents": "Eletriptan -- Administration -- Specific Patient Populations. Pediatric patients: Eletriptan has not been studied in children younger than 18, and thus, it is\u00a0not approved for use in pediatric patients due to a lack of safety and efficacy studies in this population. [4] According to AHS guidelines, no evidence suggests that administering eletriptan OT 40 mg to adolescents increases the likelihood of experiencing headache pain response after 2 hours compared to those who receive a placebo. Notably, the FDA has approved almotriptan, rizatriptan, and zolmitriptan for treating migraines in individuals aged 12 to 17. [35]"}
{"id": "article-159936_20", "title": "Eletriptan -- Administration -- Specific Patient Populations", "content": "Older patients: Eletriptan has not demonstrated geriatric-specific issues limiting its use in older patients. [1] However, caution may be warranted in older individuals due to a potentially higher prevalence of cardiovascular risk factors and age-related kidney disorders.", "contents": "Eletriptan -- Administration -- Specific Patient Populations. Older patients: Eletriptan has not demonstrated geriatric-specific issues limiting its use in older patients. [1] However, caution may be warranted in older individuals due to a potentially higher prevalence of cardiovascular risk factors and age-related kidney disorders."}
{"id": "article-159936_21", "title": "Eletriptan -- Adverse Effects", "content": "Adverse events reported from eletriptan use are mostly mild, moderate, and transient. [36] Although eletriptan is associated with nausea, dizziness, drowsiness, and coronary vasoconstriction, the most common adverse effects include a group of sensations referred to as \"triptan sensations,\" including paresthesia, flushing, tingling, chest tightness, and neck pain. [37] Additional effects, such as palpitations, headaches, chills, pain, hypertonia, hypoesthesia, diaphoresis, abdominal pain, including cramps, discomfort, and pressure, xerostomia, dysphagia, dyspepsia, pharyngitis, back pain, and generalized weakness, have been reported, albeit at a much lower incidence ranging from 1% to 7%. [32]", "contents": "Eletriptan -- Adverse Effects. Adverse events reported from eletriptan use are mostly mild, moderate, and transient. [36] Although eletriptan is associated with nausea, dizziness, drowsiness, and coronary vasoconstriction, the most common adverse effects include a group of sensations referred to as \"triptan sensations,\" including paresthesia, flushing, tingling, chest tightness, and neck pain. [37] Additional effects, such as palpitations, headaches, chills, pain, hypertonia, hypoesthesia, diaphoresis, abdominal pain, including cramps, discomfort, and pressure, xerostomia, dysphagia, dyspepsia, pharyngitis, back pain, and generalized weakness, have been reported, albeit at a much lower incidence ranging from 1% to 7%. [32]"}
{"id": "article-159936_22", "title": "Eletriptan -- Adverse Effects", "content": "In the evaluation of adverse events, it is crucial to highlight that anaphylaxis, anaphylactoid, and hypersensitivity reactions have occurred, albeit at a rate of less than 1%, and may pose a life-threatening or fatal risk. [38] In addition, 5-HT(1B/1D) agonist administration has been associated with transient cardiac ischemia, coronary artery vasospasm, myocardial infarction, cardiac arrest, ventricular tachycardia or fibrillation, stroke, hypertensive crises, vasospasm-related events, and death. As reported, serotonin syndrome is an adverse effect of eletriptan. Therefore, it is not recommended to use certain drugs that enhance the serotonergic effect of eletriptan concurrently. Clinical signs of serotonin syndrome include clonus, hyperreflexia, diaphoresis, altered mental status, tremor, autonomic instability, and hyperthermia. [39]", "contents": "Eletriptan -- Adverse Effects. In the evaluation of adverse events, it is crucial to highlight that anaphylaxis, anaphylactoid, and hypersensitivity reactions have occurred, albeit at a rate of less than 1%, and may pose a life-threatening or fatal risk. [38] In addition, 5-HT(1B/1D) agonist administration has been associated with transient cardiac ischemia, coronary artery vasospasm, myocardial infarction, cardiac arrest, ventricular tachycardia or fibrillation, stroke, hypertensive crises, vasospasm-related events, and death. As reported, serotonin syndrome is an adverse effect of eletriptan. Therefore, it is not recommended to use certain drugs that enhance the serotonergic effect of eletriptan concurrently. Clinical signs of serotonin syndrome include clonus, hyperreflexia, diaphoresis, altered mental status, tremor, autonomic instability, and hyperthermia. [39]"}
{"id": "article-159936_23", "title": "Eletriptan -- Adverse Effects -- Drug-Drug Interactions", "content": "As eletriptan is a primary substrate of the CYP3A4 enzyme, it is advised not to administer eletriptan within at least 72 hours of a potent CYP3A4 inhibitor. [40] Furthermore, eletriptan may interact with oral contraceptives due to its CYP3A4 metabolism. [29] Eletriptan should not be coadministered with monoamine oxidase inhibitors, other triptans (5-HT1D receptor agonists), or nefazodone due to the high risk of an increased serotonergic effect, which could\u00a0lead to serotonin syndrome. Although serotonergic agonists may be utilized concurrently with eletriptan therapy, close monitoring for signs and symptoms of serotonin syndrome is recommended, especially during initiation and dose increases. [7]", "contents": "Eletriptan -- Adverse Effects -- Drug-Drug Interactions. As eletriptan is a primary substrate of the CYP3A4 enzyme, it is advised not to administer eletriptan within at least 72 hours of a potent CYP3A4 inhibitor. [40] Furthermore, eletriptan may interact with oral contraceptives due to its CYP3A4 metabolism. [29] Eletriptan should not be coadministered with monoamine oxidase inhibitors, other triptans (5-HT1D receptor agonists), or nefazodone due to the high risk of an increased serotonergic effect, which could\u00a0lead to serotonin syndrome. Although serotonergic agonists may be utilized concurrently with eletriptan therapy, close monitoring for signs and symptoms of serotonin syndrome is recommended, especially during initiation and dose increases. [7]"}
{"id": "article-159936_24", "title": "Eletriptan -- Contraindications", "content": "Eletriptan is contraindicated in patients with conditions such as coronary artery vasospasm, ischemic coronary artery disease, uncontrolled hypertension, peripheral vascular disease, and ischemic bowel disease. [41] Additional cardiovascular contraindications include Wolff-Parkinson-White syndrome or cardiac accessory conduction pathway disorders. [42]", "contents": "Eletriptan -- Contraindications. Eletriptan is contraindicated in patients with conditions such as coronary artery vasospasm, ischemic coronary artery disease, uncontrolled hypertension, peripheral vascular disease, and ischemic bowel disease. [41] Additional cardiovascular contraindications include Wolff-Parkinson-White syndrome or cardiac accessory conduction pathway disorders. [42]"}
{"id": "article-159936_25", "title": "Eletriptan -- Contraindications", "content": "Eletriptan is metabolized by CYP3A4 enzymes and is contraindicated within 72 hours of recent use of potent CYP3A4 inhibitors. [43] Furthermore, eletriptan is also contraindicated if another 5-HT(1) agonist, ergotamine-containing, or ergot-type medication has been taken within the last 72 hours due to the risk of serotonin syndrome. [32] Eletriptan should be avoided in individuals with hypersensitivity reactions to prevent potential allergic responses, such as angioedema, anaphylaxis, rash, itching, swelling, or breathing difficulties. According to the FDA label, eletriptan is contraindicated in basilar or hemiplegic migraines. However, recent evidence suggests the safety of triptans in basilar migraines. [44] [45]", "contents": "Eletriptan -- Contraindications. Eletriptan is metabolized by CYP3A4 enzymes and is contraindicated within 72 hours of recent use of potent CYP3A4 inhibitors. [43] Furthermore, eletriptan is also contraindicated if another 5-HT(1) agonist, ergotamine-containing, or ergot-type medication has been taken within the last 72 hours due to the risk of serotonin syndrome. [32] Eletriptan should be avoided in individuals with hypersensitivity reactions to prevent potential allergic responses, such as angioedema, anaphylaxis, rash, itching, swelling, or breathing difficulties. According to the FDA label, eletriptan is contraindicated in basilar or hemiplegic migraines. However, recent evidence suggests the safety of triptans in basilar migraines. [44] [45]"}
{"id": "article-159936_26", "title": "Eletriptan -- Contraindications -- Box Warnings", "content": "The FDA has not issued any box warnings related to eletriptan at present.", "contents": "Eletriptan -- Contraindications -- Box Warnings. The FDA has not issued any box warnings related to eletriptan at present."}
{"id": "article-159936_27", "title": "Eletriptan -- Contraindications -- Precautions", "content": "Eletriptan use is associated with a risk of serotonin syndrome or vasospastic episodes, particularly when used concomitantly with other drugs. This risk is heightened in the geriatric population or patients with severe hepatic impairment,\u00a0which may exacerbate underlying cardiovascular conditions. [41] Thus, meticulous monitoring of cardiac function, electrocardiogram (ECG), and blood pressure is vital when prescribing eletriptan, especially for patients with known cardiac comorbidities.  Immediate discontinuation of eletriptan is necessary in the case of subarachnoid hemorrhage. [46]", "contents": "Eletriptan -- Contraindications -- Precautions. Eletriptan use is associated with a risk of serotonin syndrome or vasospastic episodes, particularly when used concomitantly with other drugs. This risk is heightened in the geriatric population or patients with severe hepatic impairment,\u00a0which may exacerbate underlying cardiovascular conditions. [41] Thus, meticulous monitoring of cardiac function, electrocardiogram (ECG), and blood pressure is vital when prescribing eletriptan, especially for patients with known cardiac comorbidities.  Immediate discontinuation of eletriptan is necessary in the case of subarachnoid hemorrhage. [46]"}
{"id": "article-159936_28", "title": "Eletriptan -- Monitoring", "content": "Patients should be monitored for any adverse effects listed in the Adverse Effects section. In addition, clinicians should assess the response to eletriptan therapy, evaluate migraine recurrence, and observe consistent responses to eletriptan. Clinicians should also assess the patient's ability to function during a migraine attack by evaluating additional common migraine symptoms such as nausea, vomiting, photophobia, and phonophobia. [18] Furthermore, clinicians can monitor response to therapy by using validated scores such as the visual analog scale and pain intensity scale. [47]", "contents": "Eletriptan -- Monitoring. Patients should be monitored for any adverse effects listed in the Adverse Effects section. In addition, clinicians should assess the response to eletriptan therapy, evaluate migraine recurrence, and observe consistent responses to eletriptan. Clinicians should also assess the patient's ability to function during a migraine attack by evaluating additional common migraine symptoms such as nausea, vomiting, photophobia, and phonophobia. [18] Furthermore, clinicians can monitor response to therapy by using validated scores such as the visual analog scale and pain intensity scale. [47]"}
{"id": "article-159936_29", "title": "Eletriptan -- Toxicity -- Signs and Symptoms of Overdose", "content": "The most prevalent signs and symptoms of eletriptan overdose align with those of other triptans, including chest pain or tightness, jaw or neck pain or tightness, shortness of breath, palpitations, dizziness, nausea, vomiting, and sweating. [32] These symptoms may indicate severe cardiovascular complications, such as myocardial ischemia due to coronary vasospasm, arrhythmia, or hypertensive crisis or emergency. Non-ST-elevation myocardial infarction (NSTEMI) due to eletriptan overdose has been reported. [48]", "contents": "Eletriptan -- Toxicity -- Signs and Symptoms of Overdose. The most prevalent signs and symptoms of eletriptan overdose align with those of other triptans, including chest pain or tightness, jaw or neck pain or tightness, shortness of breath, palpitations, dizziness, nausea, vomiting, and sweating. [32] These symptoms may indicate severe cardiovascular complications, such as myocardial ischemia due to coronary vasospasm, arrhythmia, or hypertensive crisis or emergency. Non-ST-elevation myocardial infarction (NSTEMI) due to eletriptan overdose has been reported. [48]"}
{"id": "article-159936_30", "title": "Eletriptan -- Toxicity -- Signs and Symptoms of Overdose", "content": "Other possible signs and symptoms of eletriptan overdose include headache, confusion, agitation, hallucinations, seizures, coma, stroke, cerebral hemorrhage or ischemia, peripheral vascular ischemia or infarction, gastrointestinal ischemia or infarction, renal failure, liver failure, and death.", "contents": "Eletriptan -- Toxicity -- Signs and Symptoms of Overdose. Other possible signs and symptoms of eletriptan overdose include headache, confusion, agitation, hallucinations, seizures, coma, stroke, cerebral hemorrhage or ischemia, peripheral vascular ischemia or infarction, gastrointestinal ischemia or infarction, renal failure, liver failure, and death."}
{"id": "article-159936_31", "title": "Eletriptan -- Toxicity -- Signs and Symptoms of Overdose", "content": "Eletriptan overdose can also induce serotonin syndrome, a rare but potentially fatal condition arising from an excess of serotonin in the body. Serotonin syndrome can be triggered by the concurrent use of eletriptan with other medications that elevate serotonin levels, including antidepressants, opioids, or other triptans. The symptoms of serotonin syndrome include restlessness, agitation, confusion, hallucinations, fever, sweating, shivering, muscle stiffness or twitching, tremors, ataxia, nausea, vomiting, diarrhea, and arrhythmias.\u00a0National Poison Data System data analysis indicates a low risk of severe effects or death resulting from triptan toxicity. Triptan toxidrome is characterized by tachycardia, hypertension, and drowsiness. The study also identifies a higher risk of mortality associated with advanced age and simultaneous use of benzodiazepines or tricyclic antidepressants. [49]", "contents": "Eletriptan -- Toxicity -- Signs and Symptoms of Overdose. Eletriptan overdose can also induce serotonin syndrome, a rare but potentially fatal condition arising from an excess of serotonin in the body. Serotonin syndrome can be triggered by the concurrent use of eletriptan with other medications that elevate serotonin levels, including antidepressants, opioids, or other triptans. The symptoms of serotonin syndrome include restlessness, agitation, confusion, hallucinations, fever, sweating, shivering, muscle stiffness or twitching, tremors, ataxia, nausea, vomiting, diarrhea, and arrhythmias.\u00a0National Poison Data System data analysis indicates a low risk of severe effects or death resulting from triptan toxicity. Triptan toxidrome is characterized by tachycardia, hypertension, and drowsiness. The study also identifies a higher risk of mortality associated with advanced age and simultaneous use of benzodiazepines or tricyclic antidepressants. [49]"}
{"id": "article-159936_32", "title": "Eletriptan -- Toxicity -- Management of Overdose", "content": "Although a specific antidote for triptan toxicity does not exist, it is recommended to discontinue eletriptan\u00a0therapy and initiate cyproheptadine therapy, if toxicity is suspected, particularly in the case of serotonin syndrome. Notably, eletriptan toxicity is associated with a low risk of death. [49] In managing eletriptan toxicity, the primary approaches involve decontamination, supportive care, airway management, monitoring patient vitals, and consulting with a medical toxicologist in cases of significant overdose. Due to the large volume of drug distribution, hemodialysis is unlikely to be effective.", "contents": "Eletriptan -- Toxicity -- Management of Overdose. Although a specific antidote for triptan toxicity does not exist, it is recommended to discontinue eletriptan\u00a0therapy and initiate cyproheptadine therapy, if toxicity is suspected, particularly in the case of serotonin syndrome. Notably, eletriptan toxicity is associated with a low risk of death. [49] In managing eletriptan toxicity, the primary approaches involve decontamination, supportive care, airway management, monitoring patient vitals, and consulting with a medical toxicologist in cases of significant overdose. Due to the large volume of drug distribution, hemodialysis is unlikely to be effective."}
{"id": "article-159936_33", "title": "Eletriptan -- Enhancing Healthcare Team Outcomes", "content": "Migraines are incapacitating headaches that can persist\u00a0for up to 72 hours if left untreated or treated inadequately. Patients commonly encounter accompanying symptoms such as nausea and vomiting, photophobia, and phonophobia, all of which can significantly impact the individual's daily functioning. Therefore, although the treatment of migraines is multifactorial, it is essential. [50]", "contents": "Eletriptan -- Enhancing Healthcare Team Outcomes. Migraines are incapacitating headaches that can persist\u00a0for up to 72 hours if left untreated or treated inadequately. Patients commonly encounter accompanying symptoms such as nausea and vomiting, photophobia, and phonophobia, all of which can significantly impact the individual's daily functioning. Therefore, although the treatment of migraines is multifactorial, it is essential. [50]"}
{"id": "article-159936_34", "title": "Eletriptan -- Enhancing Healthcare Team Outcomes", "content": "Quality patient education is integral to the success of migraine management plans. Patients should be informed about common migraine triggers, such as skipped meals, poor sleep, stress, alcohol, menstruation, and specific types of food. Furthermore, patients should be empowered to identify their triggers for more personalized care. [51] Although patients should be advised to avoid any unidentified triggers, it is recognized that, often, triggers cannot be entirely avoided. Therefore, pharmacological management also assumes a crucial role in migraine management. Depending on the severity and frequency of the patient's migraines, a healthcare provider may prescribe a pharmacological agent for migraine prophylaxis. Abortive pharmacological therapies, such as triptans, are recommended for use at the onset of a migraine attack.", "contents": "Eletriptan -- Enhancing Healthcare Team Outcomes. Quality patient education is integral to the success of migraine management plans. Patients should be informed about common migraine triggers, such as skipped meals, poor sleep, stress, alcohol, menstruation, and specific types of food. Furthermore, patients should be empowered to identify their triggers for more personalized care. [51] Although patients should be advised to avoid any unidentified triggers, it is recognized that, often, triggers cannot be entirely avoided. Therefore, pharmacological management also assumes a crucial role in migraine management. Depending on the severity and frequency of the patient's migraines, a healthcare provider may prescribe a pharmacological agent for migraine prophylaxis. Abortive pharmacological therapies, such as triptans, are recommended for use at the onset of a migraine attack."}
{"id": "article-159936_35", "title": "Eletriptan -- Enhancing Healthcare Team Outcomes", "content": "The interprofessional healthcare team must offer counseling to patients regarding triptan use, emphasizing that eletriptan should be taken at the onset of the migraine attack and not during the aura alone to achieve the most effective results. If eletriptan fails to provide the desired relief for a patient's migraines, the healthcare team should contemplate alternative triptans or other abortive agents. Patients should be informed about potential adverse effects and instructed to seek emergency medical treatment if severe adverse effects are suspected, such as chest pain, pressure or tightness, palpitations, altered mental status, new onset of neurological deficits, symptoms of anaphylaxis, or serotonin syndrome.", "contents": "Eletriptan -- Enhancing Healthcare Team Outcomes. The interprofessional healthcare team must offer counseling to patients regarding triptan use, emphasizing that eletriptan should be taken at the onset of the migraine attack and not during the aura alone to achieve the most effective results. If eletriptan fails to provide the desired relief for a patient's migraines, the healthcare team should contemplate alternative triptans or other abortive agents. Patients should be informed about potential adverse effects and instructed to seek emergency medical treatment if severe adverse effects are suspected, such as chest pain, pressure or tightness, palpitations, altered mental status, new onset of neurological deficits, symptoms of anaphylaxis, or serotonin syndrome."}
{"id": "article-159936_36", "title": "Eletriptan -- Enhancing Healthcare Team Outcomes", "content": "Healthcare providers should be vigilant for signs and symptoms of serotonin syndrome in patients concurrently using eletriptan with a\u00a0selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI) despite the low risk of serotonin syndrome. [52] Patients should be informed about the risk of developing eletriptan overuse headaches, defined as taking eletriptan for 10 or more days in a month. Those who require eletriptan for 10 or more days per month are suitable candidates for prophylactic migraine therapy. [53]", "contents": "Eletriptan -- Enhancing Healthcare Team Outcomes. Healthcare providers should be vigilant for signs and symptoms of serotonin syndrome in patients concurrently using eletriptan with a\u00a0selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI) despite the low risk of serotonin syndrome. [52] Patients should be informed about the risk of developing eletriptan overuse headaches, defined as taking eletriptan for 10 or more days in a month. Those who require eletriptan for 10 or more days per month are suitable candidates for prophylactic migraine therapy. [53]"}
{"id": "article-159936_37", "title": "Eletriptan -- Enhancing Healthcare Team Outcomes", "content": "Eletriptan is an effective abortive medication for the management of migraines. An evidence-based approach is crucial for managing migraines, necessitating the reassessment of the efficacy of any prophylactic or abortive pharmacological agent. Effectively managing migraines demands collaborative efforts and high-quality communication among interprofessional healthcare team members. Care coordination is vital in ensuring the patient's migraine management therapy is individualized, well-managed, and in the patient's best interest.\u00a0The healthcare team, including clinicians (MDs, DOs, NPs, and PAs), neurologists or headache specialists, nurses, and pharmacists, should work together to deliver effective, patient-centered care. This collaborative approach aims to minimize adverse events associated with eletriptan and maximize patient safety.", "contents": "Eletriptan -- Enhancing Healthcare Team Outcomes. Eletriptan is an effective abortive medication for the management of migraines. An evidence-based approach is crucial for managing migraines, necessitating the reassessment of the efficacy of any prophylactic or abortive pharmacological agent. Effectively managing migraines demands collaborative efforts and high-quality communication among interprofessional healthcare team members. Care coordination is vital in ensuring the patient's migraine management therapy is individualized, well-managed, and in the patient's best interest.\u00a0The healthcare team, including clinicians (MDs, DOs, NPs, and PAs), neurologists or headache specialists, nurses, and pharmacists, should work together to deliver effective, patient-centered care. This collaborative approach aims to minimize adverse events associated with eletriptan and maximize patient safety."}
{"id": "article-159936_38", "title": "Eletriptan -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Eletriptan -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}